CN104435205A - Salvia-miltiorrhiza-containing pharmaceutical composition for reducing blood fat - Google Patents
Salvia-miltiorrhiza-containing pharmaceutical composition for reducing blood fat Download PDFInfo
- Publication number
- CN104435205A CN104435205A CN201410628629.0A CN201410628629A CN104435205A CN 104435205 A CN104435205 A CN 104435205A CN 201410628629 A CN201410628629 A CN 201410628629A CN 104435205 A CN104435205 A CN 104435205A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- parts
- radix
- raw material
- blood fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Abstract
The invention discloses a salvia-miltiorrhiza-containing pharmaceutical composition for reducing blood fat. The salvia-miltiorrhiza-containing pharmaceutical composition is prepared from raw materials including salvia miltiorrhiza, sea buckthorns, cyclocarya paliurus, rheum officinale, hawthorn leaves and Chinese dates. Verified by pharmacologic experiments, the pharmaceutical composition disclosed by the invention has a favorable blood fat reducing effect and is exact in curative effect, small in dosage, free of toxic or side effects on a human body, simple in prescription and beneficial to popularization and application.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition of blood fat reducing, particularly a kind of pharmaceutical composition for blood fat reducing containing Radix Salviae Miltiorrhizae, being specifically related to a kind of is the pharmaceutical composition that raw material is made by Radix Salviae Miltiorrhizae, Fructus Hippophae, Cyclocarya paliurus Iljinskaja, Radix Et Rhizoma Rhei, Folium Crataegi and Fructus Jujubae.
Background technology
Along with improving constantly of people's living standard, the sickness rate of hyperlipemia is obvious ascendant trend, and hyperlipemia is again the key factor of bringing out coronary atherosclerotic heart disease (coronary heart disease), arteriosclerosis, fatty liver, diabetes, obesity etc.Therefore the blood lipid-lowering medicine finding high effect nontoxic has important realistic meaning.
Lipoprotein refers to the protein together with contaminated with lipid, comprise very low density lipoprotein (VLDL) (VLDL), low density lipoprotein, LDL (LDL), high density lipoprotein (HDL), the lipid of different lipoprotein forms the difference mainly measured, the difference of rarer matter.The chemical composition 80% ~ 90% of very low density lipoprotein (VLDL) is triacylglycerol, is the important form of body transport endogenous triacylglycerol, so when very low density lipoprotein (VLDL) raises, triacylglycerol also must raise; Low density lipoprotein, LDL is that its molecule is minimum, and cholesterol level is the highest, so when low density lipoprotein, LDL increases, cholesterol total amount must increase by the principal mode of the cholesterol transport of liver synthesis to body tissue; High density lipoprotein granule is less, protein content is the highest, can more freely to come in and go out tremulous pulse, can excrete after carrying out metabolism in the reverse cholesterol transport on arterial wall to liver, reduce the deposition of cholesterol on arterial wall, the minimizing of high density lipoprotein just means increasing of cholesterol total amount.
The Western medicine being used for the treatment of hyperlipemia is at present subject to everybody favor certainly because of its rapid-action and curative effect, but Western medicine has toxic and side effects in various degree, and Chinese medicine is in treatment hyperlipemia, prevent the aspects such as cardiovascular and cerebrovascular disease generation from having unique advantage, its curative effect certainly, lasting, side effect is little, is that Western medicine institute is incomparable.Particularly in differentiation of symptoms and signs for classification of syndrome, embody the flexible prescription of the traditional Chinese medical science, the therapeutic features of giving treatment in accordance with the patient’s individuality.Modern doctor generally believes genus deficiency in origin and excess in superficiality, blood stasis, the turbid category of expectorant for the understanding of hyperlipemia; Ahyperlipoidemia name of disease in Chinese medicine, clinical syndrome differentiation is attributed to caused by liver and kidney deficiency more, and insufficiency of the spleen expectorant is turbid, qi depression to blood stasis.Large multiplex liver and kidney tonifying during treatment, invigorating the spleen and benefiting QI, nourishing YIN and benefiting blood, blood circulation promoting and blood stasis dispelling, clearing away heat and loosing the bowels, eliminate indigestion and phlegm these medicines.
At present, treatment hyperlipemia Chinese patent medicine more, this wherein, some prescriptions are excessive, and curative effect is indefinite, and what have causes price quite high owing to employing rare medicinal herbs in side.These all make to be unfavorable for that promotion price is applied.
Summary of the invention
The object of the invention is to overcome above-mentioned deficiency existing in prior art, a kind of pharmaceutical composition for blood fat reducing containing Radix Salviae Miltiorrhizae is provided.This pharmaceutical composition has good blood fat reducing function, determined curative effect, and dosage is little, and to human non-toxic's side effect, and prescription is simple, is beneficial to and applies.
In order to realize foregoing invention object, the invention provides following technical scheme:
The pharmaceutical composition for blood fat reducing containing Radix Salviae Miltiorrhizae of the present invention, it is the medicament be made up of following raw material: Radix Salviae Miltiorrhizae, Fructus Hippophae, Cyclocarya paliurus Iljinskaja, Radix Et Rhizoma Rhei, Folium Crataegi and Fructus Jujubae.
In pharmaceutical composition of the present invention, Radix Salviae Miltiorrhizae, nature and flavor are bitter, are slightly cold.GUIXIN, Liver Channel.There is stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, the effect of the relieving restlessness that clears away heart-fire.For menoxenia, amenorrhea dysmenorrhea, lump in the abdomen, breast ventral spine pain, pyretic arthralgia pain, skin infection swells and ache, dysphoria and insomnia; Hepatosplenomegaly, angina pectoris.
Fructus Hippophae, sour-puckery flavor warm in nature.Eliminating phlegm and stopping cough, relieving dyspepsia, promoting blood circulation to remove blood stasis.For cough with copious phlegm, dyspepsia, abdominal pain due to retention of food, fall and flutter congestive edema, blood stasis amenorrhea.
Cyclocarya paliurus Iljinskaja, has clearing heat for detumescence, effect of pain relieving.
Radix Et Rhizoma Rhei, bitter in the mouth, cold in nature, return spleen, stomach, large intestine, liver, pericardium channel.Purging heat and dredging bowels, removing pathogenic heat from blood and toxic substance from the body, eliminating blood stasis and inducing menstruation.For excess-heat constipation, stagnant stomachache, dysentery is not well, jaundice due to damp-heat, and heat in blood tells nosebleed, conjunctival congestion, pharyngeal swelling, abdominalgia with intestinal abscess, carbuncle furuncle, blood stasis amenorrhea, traumatic injury, burn due to hot liquid or fire; Upper gastrointestinal hemorrhage.
Folium Crataegi, property acid; Flat; Return lung meridian, cure mainly antipruritic, sore, blood pressure lowering, main dermatitis rhus, ulcer being unable to heal, hypertension.
Fructus Jujubae, sweet, warm.Return spleen, stomach warp.Invigorating the spleen and replenishing QI, nourishing blood to tranquillize the mind.For insufficiency of the spleen lack of appetite, weak loose stool, woman hysteria.
Applicant finds through test of many times, is that pharmaceutical composition made by raw material by Radix Salviae Miltiorrhizae, Fructus Hippophae, Cyclocarya paliurus Iljinskaja, Radix Et Rhizoma Rhei, Folium Crataegi and Fructus Jujubae, can effectively blood fat reducing.
Preferably, described pharmaceutical composition is made up of the raw material of following weight: Radix Salviae Miltiorrhizae 5 ~ 25 parts, Fructus Hippophae 4 ~ 18 parts, Cyclocarya paliurus Iljinskaja 1 ~ 12 part, Radix Et Rhizoma Rhei 1 ~ 12 part, Folium Crataegi 1 ~ 8 part and 1 ~ 8 part, Fructus Jujubae.
Applicant finds through many experiments, and pharmaceutical composition of the present invention is made up of the raw material of above-mentioned weight, better can play the synergistic function of each raw material components, not only can effectively blood fat reducing, simultaneously instant effect, and dosage is little, has no side effect.
Further preferably, described pharmaceutical composition is made up of the raw material of following weight: Radix Salviae Miltiorrhizae 8 ~ 20 parts, Fructus Hippophae 5 ~ 15 parts, Cyclocarya paliurus Iljinskaja 3 ~ 10 parts, Radix Et Rhizoma Rhei 3 ~ 9 parts, Folium Crataegi 1 ~ 5 part and 2 ~ 7 parts, Fructus Jujubae.
Still more preferably, described pharmaceutical composition is made up of the raw material of following weight: Radix Salviae Miltiorrhizae 10 ~ 15 parts, Fructus Hippophae 6 ~ 10 parts, Cyclocarya paliurus Iljinskaja 5 ~ 8 parts, Radix Et Rhizoma Rhei 4 ~ 7 parts, Folium Crataegi 2 ~ 4 parts and 2 ~ 5 parts, Fructus Jujubae.
Preferably, to the best described pharmaceutical composition be made up of the raw material of following weight: Radix Salviae Miltiorrhizae 12 parts, Fructus Hippophae 8 parts, Cyclocarya paliurus Iljinskaja 6 parts, Radix Et Rhizoma Rhei 6 parts, Folium Crataegi 3 parts and 3 parts, Fructus Jujubae.
By preferably above, the curative effect of pharmaceutical composition can be improved further.
The dosage form of pharmaceutical composition of the present invention can be the existing pharmaceutical dosage form of any one in drop pill, tablet, capsule, soft capsule, powder, oral liquid, granule.
The preparation method of pharmaceutical composition of the present invention is as follows:
The raw material of above-mentioned weight is added respectively 50 ~ 70% ethanol of 8 ~ 10 times of volumes, reflux, extract, three times, extraction time is respectively 2.0h, 1.5h, 1.5h, filter, merge 3 filtrates, after recovery ethanol also concentrates, by each concentrated solution mix homogeneously, drying, makes acceptable various pharmaceutical dosage form.
According to the needs of the various drug form of preparation, medicine of the present invention also can add suitable pharmaceutic adjuvant as filler, disintegrating agent, binding agent, lubricant, antiseptic etc. in preparation process.
Preparation method of the present invention effectively can extract the effective ingredient in each crude drug, makes it better play the effect of Synergistic.
The present invention's various raw medicinal materials used are the Chinese crude drug meeting country or provincial standard and specify.The pharmaceutical composition of blood fat reducing of the present invention, based on theory of Chinese medical science, in conjunction with clinical practice, from Chinese medicine material treasure-house, filter out Radix Salviae Miltiorrhizae, Fructus Hippophae, Cyclocarya paliurus Iljinskaja, Radix Et Rhizoma Rhei, Folium Crataegi and the pure purification of tcm of Fructus Jujubae Six-element form, and regulate the weight of each raw material, and make the effect playing Synergistic between each raw material, can effectively blood fat reducing, heat clearing away suppressing the hyperactive liver, reduces phlegm and invigorates blood circulation.Pharmaceutical composition instant effect of the present invention simultaneously, dosage is little, has no side effect.
Detailed description of the invention
Below in conjunction with test example and detailed description of the invention, the present invention is described in further detail.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment, all technology realized based on content of the present invention all belong to scope of the present invention.
Embodiment 1
The pharmaceutical composition of the blood fat reducing described in the present embodiment, be made up of the raw material of following weight:
Radix Salviae Miltiorrhizae 12g, Fructus Hippophae 8g, Cyclocarya paliurus Iljinskaja 6g, Radix Et Rhizoma Rhei 6g, Folium Crataegi 3g and Fructus Jujubae 3g.
Above-mentioned raw materials is prepared into granule, and preparation method is as follows:
The raw material of above-mentioned weight is added respectively 60% ethanol of 8 times of volumes, reflux, extract, three times, extraction time is respectively 2.0h, 1.5h, 1.5h, filters, merge 3 filtrates, after recovery ethanol also concentrates, by each concentrated solution mix homogeneously, dry, add 100g dextrin again, mixing, is distributed into bag, obtains the pharmaceutical composition of granule.
Embodiment 2
The pharmaceutical composition of blood fat reducing described in the present embodiment, be made up of the raw material of following weight:
Radix Salviae Miltiorrhizae 5g, Fructus Hippophae 18g, Cyclocarya paliurus Iljinskaja 2g, Radix Et Rhizoma Rhei 2g, Folium Crataegi 8g and Fructus Jujubae 8g.
Above-mentioned raw materials is prepared into tablet, and preparation method is as follows:
The raw material of above-mentioned weight is added respectively 70% ethanol of 10 times of volumes, reflux, extract, three times, extraction time is respectively 2.0h, 1.5h, 1.5h, filter, merge 3 filtrates, after recovery ethanol also concentrates, by each concentrated solution mix homogeneously, dry, mix homogeneously, then with 100g starch, 10g polyvidone mixes, adopt existing pressed-disc technique, make the pharmaceutical composition of tablet.
Embodiment 3
The pharmaceutical composition of blood fat reducing described in the present embodiment, be made up of the raw material of following weight:
Radix Salviae Miltiorrhizae 25g, Fructus Hippophae 4g, Cyclocarya paliurus Iljinskaja 10g, Radix Et Rhizoma Rhei 6g, Folium Crataegi 2g and Fructus Jujubae 2g.
Above-mentioned raw materials is prepared into powder, and preparation method is as follows:
The raw material of above-mentioned weight is added respectively 50% ethanol of 9 times of volumes, reflux, extract, three times, extraction time is respectively 2.0h, 1.5h, 1.5h, filter, merge 3 filtrates, after recovery ethanol also concentrates, by each concentrated solution mix homogeneously, dry, then with 100g sucrose, mixing, according to the preparation technique of powder, make powder, be distributed into bag.
Embodiment 4
The pharmaceutical composition of blood fat reducing described in the present embodiment, be made up of the raw material of following weight:
Radix Salviae Miltiorrhizae 10g, Fructus Hippophae 6g, Cyclocarya paliurus Iljinskaja 5g, Radix Et Rhizoma Rhei 12g, Folium Crataegi 7g and Fructus Jujubae 8g.
Above-mentioned raw materials is prepared into granule, and preparation method is as follows:
The raw material of above-mentioned weight is added respectively 70% ethanol of 8 times of volumes, reflux, extract, three times, extraction time is respectively 2.0h, 1.5h, 1.5h, filters, merge 3 filtrates, after recovery ethanol also concentrates, by each concentrated solution mix homogeneously, dry, then with 25g vegetable oil, mixing, using ' Yanming ' capsules for clearing as capsule casing material, makes soft capsule.
Comparative example 1
The pharmaceutical composition of the blood fat reducing described in this comparative example, be made up of the raw material of following weight:
Fructus Hippophae 8g, Cyclocarya paliurus Iljinskaja 6g, Radix Et Rhizoma Rhei 6g, Folium Crataegi 3g and Fructus Jujubae 3g.
Adopt the preparation method described in embodiment 1, make the pharmaceutical composition of granule.
Comparative example 2
The pharmaceutical composition of the blood fat reducing described in the present embodiment, be made up of the raw material of following weight:
Radix Salviae Miltiorrhizae 12g, Fructus Hippophae 8g, Cyclocarya paliurus Iljinskaja 6g, Folium Crataegi 3g and Fructus Jujubae 3g.
Adopt the preparation method described in embodiment 1, make the pharmaceutical composition of granule.
Embodiment 5
1. laboratory animal: healthy Kunming mouse, body weight 20-25g, male and female half and half;
2, Experimental agents: cholesterol, propylthiouracil.
3, experiment grouping:
Get healthy Kunming mouse 80, be divided into 8 groups at random, namely blank group, model group, positive drug group (administration simvastatin), embodiment 1 group (administration embodiment 1 prepare pharmaceutical composition), embodiment 2 groups (pharmaceutical composition prepared by administration embodiment 2), embodiment 3 groups (pharmaceutical composition prepared by administration embodiment 3), comparative example 1 group (pharmaceutical composition prepared by administration comparative example 1), comparative example 2 groups (pharmaceutical composition prepared by administration comparative example 2), often organize 10, male and female half and half.
Each group of morning gives gastric infusion, gavage solution is prepared with 2% tween solution, gavage capacity 20ml/kgBW, each group of embodiment 1-3, comparative example 1-2 respectively organize dosage and are 10g/kg by crude drug gauge, the dosage of simvastatin is 0.04g/kg, and blank, model group gives equivalent 2% tween solution.
4, experimental technique:
The preparation of 4.1 fat milks:
Get 1g propylthiouracil porphyrize in mortar, for subsequent use; Get 20g Adeps Sus domestica to melt in 40 DEG C of heating in water bath, put in mortar, add 10g cholesterol, 1g propylthiouracil, fully stir, dissolve; Slowly add 10% deoxycholic acid sodium water solution 20ml again, and constantly stir, then add 5ml Tween 80, grinding emulsifying is even, and last adding distil water is to 100ml; Load in hermetic container, cold preservation, obtains fat milk.Fat milk is melting prior to 37 DEG C of water-baths before use.
4.2 modeling methods: except blank group, all the other are respectively organized mice and all give gavage fat milk 20ml/kgBW, continuous 2 weeks.
5, Testing index
TG, TC level determination in 5.1 serum: after last gavage, water 12h is can't help in fasting, gets blood, according to test kit, mensuration TC, TG level is described.
MDA content and SOD determination of activity in 5.2 livers: mice is put to death after getting blood, wins liver 0.5g, rinses in normal saline, filter paper blots, make the liver homogenate liquid of 10% with normal saline homogenate, centrifuging and taking supernatant, illustrate according to test kit and measure MDA content and SOD activity.
6. statistical method: adopt SPSS13.0 software to carry out one factor analysis of variance to experimental data, every data all with
represent.
7. result:
7.1 impacts on serum TC, TG level: in table 1
Table 1: pharmaceutical composition of the present invention on the impact of mice serum TC, TG (
n=10)
| Group | Dosage (g/kg) | TC(mmol/L) | TG(mmol/L) |
| Normal group | / | 3.05±0.56 | 0.43±0.14 |
| Model group | / | 5.31±0.62 ## | 0.77±0.16 ## |
| Positive controls | 0.04 | 3.59±0.49 ** | 0.55±0.17 * |
| Embodiment 1 group | 10 | 3.67±0.54 **&▲ | 0.60±0.18 |
| Embodiment 2 groups | 10 | 4.01±0.55 **&▲ | 0.67±0.18 |
| Embodiment 3 groups | 10 | 3.94±0.56 **&▲ | 0.68±0.21 |
| Comparative example 1 group | 10 | 4.78±0.56 * | 0.73±0.18 |
| Comparative example 2 groups | 10 | 4.63±0.61 * | 0.72±0.17 |
Note: compare with normal group,
##p < 0.01; Compare with model group,
*p < 0.05,
*p < 0.01; Compared with comparative example 1 group,
aMP.AMp.Ampp < 0.05; Compared with comparative example 2 groups,
▲p < 0.05.
Table 1 result shows:
Compare with normal group, in model group mice serum, TC and TG content is in various degree higher than normal group, and difference has statistical significance (P < 0.01), shows modeling success.
Compare with model group, positive controls reduces the content of TC, TG in mice serum, has significant difference (P < 0.01); Compare with model group, embodiment 1-3 group reduces TC and TG content, has significant difference (P < 0.01), shows that pharmaceutical composition of the present invention can effectively blood fat reducing.
Compare with 2 groups with comparative example 1, embodiment 1-3 respectively organizes TC and TG content in mice serum and obviously reduces (P < 0.05); Show in pharmaceutical composition of the present invention to be Synergistic between each raw material, lack effect that any Herba indigoferae Pseudotinctoriae all significantly can reduce pharmaceutical composition.
7.2 impacts on liver MDA content and SOD activity: in table 2
Table 2: on the impact of liver MDA content and SOD activity (
n=10)
| Group | Dosage (g/kg) | MDA(nmol/ml) | SOD(U/ml) |
| Normal group | / | 3.84±1.16 | 183.25±11.58 |
| Model group | / | 7.46±1.18 ## | 140.26±11.64 ## |
| Positive controls | 0.04 | 4.01±1.21 ** | 177.34±12.48 ** |
| Embodiment 1 group | 10 | 4.69±1.15 **&▲ | 176.54±12.06 **&▲ |
| Embodiment 2 groups | 10 | 5.22±1.24 **&▲ | 170.23±11.73 **&▲ |
| Embodiment 3 groups | 10 | 5.25±1.17 **&▲ | 169.85±12.16 **&▲ |
| Comparative example 1 group | 10 | 6.30±1.15 * | 150.62±11.64 * |
| Comparative example 2 groups | 10 | 6.24±1.18 * | 155.69±11.89 * |
Note: compare with normal group,
##p < 0.01; Compare with model group,
*p < 0.05,
*p < 0.01; Compared with comparative example 1 group,
aMP.AMp.Ampp < 0.05; Compared with comparative example 2 groups,
▲p < 0.05.
Table 2 result shows:
Compare with normal group, in model group mouse liver, MDA content significantly raises, and SOD is active significantly reduces (P < 0.01), shows modeling success.
Compare with model group, positive controls MDA content obviously reduces, and SOD is active obviously raises (P < 0.01); Compare with model group, embodiment 1-3 group MDA content significantly reduces, and SOD is active significantly raises (P < 0.01), shows that pharmaceutical composition of the present invention can effectively blood fat reducing.
Compared with comparative example 1-2 group, embodiment 1-3 respectively organizes MDA content in mouse liver and obviously reduces, SOD is active obviously raises (P < 0.05), show in pharmaceutical composition of the present invention to be Synergistic between each raw material, lack effect that any Herba indigoferae Pseudotinctoriae all significantly can reduce pharmaceutical composition.
Claims (5)
1. the pharmaceutical composition for blood fat reducing containing Radix Salviae Miltiorrhizae, it is characterized in that, it is the medicament be made up of following raw material: Radix Salviae Miltiorrhizae, Fructus Hippophae, Cyclocarya paliurus Iljinskaja, Radix Et Rhizoma Rhei, Folium Crataegi and Fructus Jujubae.
2. pharmaceutical composition according to claim 1, is characterized in that, the weight of described each raw material is: Radix Salviae Miltiorrhizae 5 ~ 25 parts, Fructus Hippophae 4 ~ 18 parts, Cyclocarya paliurus Iljinskaja 1 ~ 12 part, Radix Et Rhizoma Rhei 1 ~ 12 part, Folium Crataegi 1 ~ 8 part and 1 ~ 8 part, Fructus Jujubae.
3. pharmaceutical composition according to claim 2, is characterized in that, the weight of described each raw material is: Radix Salviae Miltiorrhizae 8 ~ 20 parts, Fructus Hippophae 5 ~ 15 parts, Cyclocarya paliurus Iljinskaja 3 ~ 10 parts, Radix Et Rhizoma Rhei 3 ~ 9 parts, Folium Crataegi 1 ~ 5 part and 2 ~ 7 parts, Fructus Jujubae.
4. pharmaceutical composition according to claim 3, is characterized in that, the weight of described each raw material is: Radix Salviae Miltiorrhizae 10 ~ 15 parts, Fructus Hippophae 6 ~ 10 parts, Cyclocarya paliurus Iljinskaja 5 ~ 8 parts, Radix Et Rhizoma Rhei 4 ~ 7 parts, Folium Crataegi 2 ~ 4 parts and 2 ~ 5 parts, Fructus Jujubae.
5. pharmaceutical composition according to claim 4, is characterized in that, the weight of described each raw material is: Radix Salviae Miltiorrhizae 12 parts, Fructus Hippophae 8 parts, Cyclocarya paliurus Iljinskaja 6 parts, Radix Et Rhizoma Rhei 6 parts, Folium Crataegi 3 parts and 3 parts, Fructus Jujubae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410628629.0A CN104435205A (en) | 2014-11-10 | 2014-11-10 | Salvia-miltiorrhiza-containing pharmaceutical composition for reducing blood fat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410628629.0A CN104435205A (en) | 2014-11-10 | 2014-11-10 | Salvia-miltiorrhiza-containing pharmaceutical composition for reducing blood fat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104435205A true CN104435205A (en) | 2015-03-25 |
Family
ID=52882467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410628629.0A Pending CN104435205A (en) | 2014-11-10 | 2014-11-10 | Salvia-miltiorrhiza-containing pharmaceutical composition for reducing blood fat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104435205A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108186723A (en) * | 2018-03-15 | 2018-06-22 | 广西中医药大学 | Blue or green money willow extract and its application of preparation and reducing blood lipid |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101288705A (en) * | 2007-04-18 | 2008-10-22 | 北京本草天源药物研究院 | Medicine composition mainly for adjusting blood fat and its preparation method |
| CN102631425A (en) * | 2012-03-30 | 2012-08-15 | 乔俊缠 | Mongolian medicine for treating dyslipidemia |
| CN103721215A (en) * | 2012-10-15 | 2014-04-16 | 戴秀芳 | Chinese medicinal composition for treating hyperlipemia |
-
2014
- 2014-11-10 CN CN201410628629.0A patent/CN104435205A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101288705A (en) * | 2007-04-18 | 2008-10-22 | 北京本草天源药物研究院 | Medicine composition mainly for adjusting blood fat and its preparation method |
| CN102631425A (en) * | 2012-03-30 | 2012-08-15 | 乔俊缠 | Mongolian medicine for treating dyslipidemia |
| CN103721215A (en) * | 2012-10-15 | 2014-04-16 | 戴秀芳 | Chinese medicinal composition for treating hyperlipemia |
Non-Patent Citations (2)
| Title |
|---|
| 万明等: "《农业常用技术》", 31 March 2008, 江西科学技术出版社 * |
| 马明丽等: "中医药降血脂实验研究的最新进展", 《辽宁中医杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108186723A (en) * | 2018-03-15 | 2018-06-22 | 广西中医药大学 | Blue or green money willow extract and its application of preparation and reducing blood lipid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN103463494B (en) | One treats hypertensive Chinese medicine preparation | |
| CN103933498A (en) | Drug for treatment of chronic atrophic gastritis and preparation method thereof | |
| CN103989820B (en) | Medicament for treating hyperlipidemia | |
| JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
| CN105999058B (en) | Bidens bipinnata lipid-lowering tablet | |
| CN104435772A (en) | Hawthorn-containing pharmaceutical composition for reducing blood fat | |
| CN104435205A (en) | Salvia-miltiorrhiza-containing pharmaceutical composition for reducing blood fat | |
| CN101116686A (en) | Medicine for treating fatness and its complication | |
| CN103394002A (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN103751650B (en) | One treats paracmastic Chinese medicine composition of gout and preparation method thereof | |
| CN102389465B (en) | Traditional Chinese medicine composition for treating gastropathy and its preparation method | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN104367947A (en) | Rhizoma panacis majoris-containing pharmaceutical composition for lowering blood fat | |
| CN104383349A (en) | Drug for postoperative recovery of bladder cancer and preparation method of drug for postoperative recovery of bladder cancer | |
| CN104306847A (en) | Six-ingredient qi-tonifying capsule and preparation process thereof | |
| CN102100814A (en) | Method for preparing nanometer traditional Chinese medicine for treating severe asthma and production method thereof | |
| CN104435877A (en) | Radix-puerariae-containing pharmaceutical composition for reducing blood fat | |
| CN104367653A (en) | Codonopsis pilosula-containing pharmaceutical composition for lowering blood fat | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN104367840A (en) | Astragalus root-containing pharmaceutical composition for lowering blood fat | |
| CN104367731A (en) | Plantain seed-containing pharmaceutical composition for lowering blood fat | |
| CN104367642A (en) | Polygonum multiflorum-containing pharmaceutical composition for lowering blood fat | |
| CN1063074C (en) | Chinese herbs injection for treating oncoma (cancer) and preparation method | |
| CN105596893A (en) | Traditional Chinese medicine composition for treating hyperlipidaemia and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150325 |